Skip to main content
. 2012 Dec 11;7(12):e51461. doi: 10.1371/journal.pone.0051461

Figure 2. SM-164 enhances APO2L/TRAIL-mediated anticancer activity in HCC cells.

Figure 2

(a–d). BEL-7402, SMMC-7721, HepG2 and Hep3B cell lines were treated with APO2L/TRAIL (A/TR) alone, or in combination with SM-164 at 0.1 µM (SM+ A/TR) for 4 d, cell viability inhibition was determined using an MTT assay. (e-f). SMMC-7721 and HepG2 cells were seeded into six-well plates at 600 cells per well in triplicates, and treated with SM-164 alone, A/TR alone or their combination (SM+ A/TR) for 2 weeks, followed by 0.05% methylene blue staining and colony counting. (left panels), representative results show photographs of stained 6-well plates for SMMC-7721 and HepG2, respectively. (right panels), data show means ± S.D. Normal human liver cell line L02 was treated as indicated for 4 d, cell viability inhibition was determined using an MTT assay. *, p<0.05, * *, p<0.01.